<DOC>
	<DOC>NCT00689325</DOC>
	<brief_summary>To evaluate the QOL (subjective effectiveness) in patients with schizophrenia, treated with atypical antipsychotics.</brief_summary>
	<brief_title>Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXRÂ® and Other Atypical Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis of schizophrenia Treatment with one atypical antipsychotic* (for a first/new episode or a switch of therapy) for at least 2 weeks and maximum 8 weeks prior to the first study visit. Patient takes an AAP according to local SPC and current medical practice The patient must be able to understand and comply with the study requirements as judged by the investigator, e.g. patient must be able to read and write Treatment with an additional AAP or AP to the initial prescribed AAP within the 28 weeks before the patient is included in the study Since the use of clozapine is limited, due to, among other things, the risk for agranulocytosis, patients on treatment with this '2nd line'AAP are excluded. Previous enrolment or treatment in the present NIS Known allergy to the prescribed AAP or any of its substances</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>remission</keyword>
	<keyword>subjective well-being and effectiveness</keyword>
	<keyword>Quality of Life</keyword>
</DOC>